ScinoPharm Taiwan, Ltd. · TWSE:1789
ScinoPharm Taiwan — Investor Presentation (November 2013)
26 slides from ScinoPharm Taiwan's investor presentation, Nov 12, 2013
Slide 1: ScinoPharm Management Presentation
ScinoPharm Management Presentation TWSE 1789 November 12, 2013 1
Slide 2: Disclaimer
Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.
Slide 3: Table of Content
Table of Content Overview of ScinoPharm Financial & Operating Results Stable Long Term Partnership First Launch of Double A Strategy Business Outlook 3
Slide 4: Overview of ScinoPharm - An API + ANDA Company
Overview of ScinoPharm - An API + ANDA Company Active Pharmaceutical Ingredients Abbreviated New Drug Application 4
Slide 5: Background
Background Established in 1997 in Taiwan by founders from Syntex, listed on TWSE, current market cap ~ US$ 2.1 billion Major shareholders include Uni-President Group, Government’s Development Fund, Taiwan Sugar, etc. Facility & organization designed & built in Taiwan by experienced Syntex team
Slide 6: Business Overview
Business Overview Maintain dominant position in Specialty APIs for generic market. Strong customer base (320+) in US/EU/Japan, some through Indian generics. Aggressively developing Japan and China markets Developed ~70 generic APIs with 23 launched. Filed 45 DMFs in US (658 DMFs WW), leader in s
Slide 7: World Class Facilities
World Class Facilities Taiwan (SPT) China (SPC) 6.6 hectares of land, 330K sq. ft. facilities 6.6 hectares of land with ~250M3 reactor with >200M3 reactor volume volume 8 of 18 production lines equipped with 1st phase completed in Q1, 2012 high potency capabilities for cytotoxics 2nd phase c
Slide 8: Financial & Operating Results
Financial & Operating Results 8
Slide 9: Cumulative P&L - Consolidated
Cumulative P&L - Consolidated 1Q~3Q,’13 1Q~3Q,’12 In NT$ million, except for EPS YoY (Reviewed) (Reviewed) Net Sales 3,764 3,168 19% Gross Profit 1,909 1,601 19% Gross margin 51% 50% Operating Expenses (794) (735) 8% Operating Income 1,115 866 29% Operating margin 30% 27% Other Rev.(Exp.) 20 16 25%
Slide 10: Balance Sheet - Consolidated
Balance Sheet- Consolidated 2013/09/30 2012/09/30 In NT$ million (Reviewed) (Reviewed) Cash and Cash Equivalents 2,734 25% 2,303 24% Accounts Receivable 689 6% 959 10% Inventories 2,359 21% 1,962 20% Long-Term Investments 264 2% 168 2% Fixed Assets 4,020 36% 3,265 34% Total Assets 11,120 100% 9,571
Slide 11: Cash Flows - Consolidated
Cash Flows- Consolidated 1Q~3Q 2013 1Q~3Q 2012 In NT$ million (Reviewed) (Reviewed) Cash and cash equivalents at 3,035 3,294 beginning of period Cash flows from operating activities 971 280 CAPEX (866) (619) Long-term Investment (107) - Short-term borrowings 479 - Cash Dividends (780) (631) Others 2
Slide 12: Sales by Business
Sales by Business 1Q~3Q 2012 1Q~3Q 2013 CRO 3% CMO CMO 15% 27% Generic Generic 82% 73% CRO <1% 12
Slide 13: Sales by Indications
Sales by Indications 1Q~3Q 2012 1Q~3Q 2013 Others Others 12% 9% Oncology CNS CNS Oncology 57% 33% 31% 58% 13
Slide 14: Sales by Region
Sales by Region 1Q~3Q 2012 1Q~3Q 2013 Rest of AU & NZ ROW Asia Rest of AU & NZ ROW 4% <1% Asia 4% <1% 9% 12% India India 11% 13% US & CAN US & CAN EU 47% 50% 29% EU 21% 14
Slide 15: Stable Long Term Partnership
Stable Long Term Partnership 15
Slide 16: Prolonged Business Building Process
Prolonged Business Building Process NCE NCE Clinical Clinical 1 Yr before Patent NDA Filing Commercial Patent Protection Customers Phase II Phase III Launch Expiry Launch Develop Provide Commercial Supply ScinoPharm API Clinical Scale Continuous Supply Agreement Process Material Production 1 Yr befo
Slide 17: Stable Partnership with Customers
Stable Partnership with Customers • ScinoPharm has many Supply Agreements (S.A.) with customers to secure mid- to long-term sales growth • High entry barriers to API sourcing: US/EU markets apply the same stringent standards for API as for drug products. Changing the API supplier would be extremely
Slide 18: Long Term Sales Increasing
Long Term Sales Increasing # of S.A. Cumulative # and sales from S.A. during 2006-2012 Sales (US$ MM) 90 80.00 80 年度供貨協議新增數 New Supply Agreements 70.00 年度供貨協議累計數 Cumulative Supply Agreements 70 Sales from S.A. 供貨協議銷售額 60.00 60 50.00 50 40.00 40 30.00 30 20.00 20 10 10.00 0 0.00 2006 2007 2008 2009 2
Slide 19: First Launch of Double A Strategy
First Launch of Double A Strategy 19
Slide 20: First Formulation Product Launch
First Formulation Product Launch Under our Double A strategy, Entecavir is the 1st formulation extending the values from our specialty API to ANDA API advantages: ScinoPharm started to develop Entecavir 7-8 years before the patent expires. We successfully developed highly efficient process technol
Slide 21: Huge Potential for Hepatitis B Drugs
Huge Potential for Hepatitis B Drugs Hepatitis B is a chronic inflammation of liver, which in the longer term may induce liver cirrhosis, and ultimately cause liver cancer. According to WHO statistics, 350 million people globally are diagnosed with hepatitis B, 75% of them in Asia. The treatment
Slide 22: ScinoPharm Successfully Developed a New Generation of Hepatitis B Drug
ScinoPharm Successfully Developed a New Generation of Hepatitis B Drug Entecavir is a new generation, high potent oral drug for treating hepatitis B. This drug not only effectively reduces the amount of the hepatitis B virus to undetectable levels, but also causes no drug resistance. In 2012, En
Slide 23: Business Outlook
Business Outlook 23
Slide 24: 2013 Product Launch Plan
2013 Product Launch Plan Brand API Region Indications Marketer Regional Sales WW Sales MDS, Azacitidine US Pharmion US$331.3MM* US$729.7MM* Anti-neoplastic MDS, Decitabine US MGI Pharma US$238.0MM* US$249.1MM* Anti-neoplastic Docetaxel JP Anti-neoplastic Sanofi Aventis US$236.9MM** US$2,051MM* Anhyd
Slide 25: Outlook
Outlook Sustain Leadership in Oncological APIs Continue to launch and develop oncological injectable APIs & others with high technological barriers including Peptides Establish Presences in China Develop APIs and formulations to timely capture the generic business with strategic alliance and CRA
Slide 26: Brand Quality with Asian Advantages
Confidential Brand Quality with Asian Advantages www.scinopharm.com 26
ScinoPharm Taiwan — Investor Presentation (November 2013) on 6ix